{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,10,8]],"date-time":"2025-10-08T09:41:38Z","timestamp":1759916498458,"version":"build-2065373602"},"reference-count":30,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2019,5,1]],"date-time":"2019-05-01T00:00:00Z","timestamp":1556668800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2019,5,1]],"date-time":"2019-05-01T00:00:00Z","timestamp":1556668800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"funder":[{"name":"County Council of \u00d6sterg\u00f6tland, Sweden","award":["LiO-11877","LiO-31321","LiO-79951"],"award-info":[{"award-number":["LiO-11877","LiO-31321","LiO-79951"]}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","maturitas.org","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Maturitas"],"published-print":{"date-parts":[[2019,5]]},"DOI":"10.1016\/j.maturitas.2019.02.009","type":"journal-article","created":{"date-parts":[[2019,2,25]],"date-time":"2019-02-25T03:04:27Z","timestamp":1551063867000},"page":"55-60","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":1,"special_numbering":"C","title":["Use of hormone therapy (HT) among Swedish women with contraindications \u2013 A pharmacoepidemiological cohort study"],"prefix":"10.1016","volume":"123","author":[{"given":"Lotta","family":"Lindh-\u00c5strand","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9420-3316","authenticated-orcid":false,"given":"Mikael","family":"Hoffmann","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mats","family":"Fredrikson","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mats","family":"Hammar","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Anna-Clara","family":"Spetz Holm","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"issue":"4","key":"10.1016\/j.maturitas.2019.02.009_bib0005","article-title":"Oral oestrogen and combined oestrogen\/progestogen therapy versus placebo for hot flushes","author":"Maclennan","year":"2004","journal-title":"Cochrane Database Syst. Rev."},{"issue":"3","key":"10.1016\/j.maturitas.2019.02.009_bib0010","doi-asserted-by":"crossref","first-page":"316","DOI":"10.3109\/13697137.2013.795683","article-title":"Updated 2013 International Menopause Society recommendations on menopausal hormone therapy and preventive strategies for midlife health","volume":"16","author":"de Villiers","year":"2013","journal-title":"Climacteric"},{"issue":"2","key":"10.1016\/j.maturitas.2019.02.009_bib0015","doi-asserted-by":"crossref","first-page":"109","DOI":"10.3109\/13697137.2015.1129166","article-title":"IMS Recommendation on women\u2019s midlife health and menopuse hormone therapy","volume":"19","author":"Baber","year":"2016","journal-title":"Climacteric"},{"issue":"25","key":"10.1016\/j.maturitas.2019.02.009_bib0020","doi-asserted-by":"crossref","first-page":"2962","DOI":"10.1161\/01.CIR.0000019406.74017.B2","article-title":"Statin therapy, cardiovascular events, and total mortality in the Heart and Estrogen\/Progestin Replacement Study (HERS)","volume":"105","author":"Herrington","year":"2002","journal-title":"Circulation"},{"issue":"3","key":"10.1016\/j.maturitas.2019.02.009_bib0025","doi-asserted-by":"crossref","first-page":"321","DOI":"10.1001\/jama.288.3.321","article-title":"Risks and benefits of estrogen plus progestin in healthy postmenopausal women: principal results From the Women\u2019s Health Initiative randomized controlled trial","volume":"288","author":"Rossouw","year":"2002","journal-title":"JAMA"},{"issue":"7419","key":"10.1016\/j.maturitas.2019.02.009_bib0030","doi-asserted-by":"crossref","first-page":"845","DOI":"10.1136\/bmj.327.7419.845","article-title":"Changes in use of hormone replacemnet therapy after the report from Women\u2019s Health Initiati: a cross sectional survey of users","volume":"327","author":"Lawton","year":"2003","journal-title":"BMJ"},{"issue":"9382","key":"10.1016\/j.maturitas.2019.02.009_bib0035","doi-asserted-by":"crossref","first-page":"419","DOI":"10.1016\/S0140-6736(03)14065-2","article-title":"Breast cancer and hormone replacement therapy in the Million Women Study","volume":"362","author":"Beral","year":"2003","journal-title":"Lancet"},{"issue":"1","key":"10.1016\/j.maturitas.2019.02.009_bib0040","article-title":"Long-term hormone therapy for perimenopausla and postmenopausal women","volume":"17","author":"Marjoribanks","year":"2017","journal-title":"Cochrane Database Syst. Rev."},{"issue":"3","key":"10.1016\/j.maturitas.2019.02.009_bib0045","doi-asserted-by":"crossref","first-page":"184","DOI":"10.7326\/0003-4819-140-3-200402030-00009","article-title":"Change in the use of postmenopausal Changes in the use of postmenopausal hormone therapy after the publication of clinical trial results","volume":"140","author":"Haas","year":"2004","journal-title":"Ann. Intern. Med."},{"issue":"1","key":"10.1016\/j.maturitas.2019.02.009_bib0050","doi-asserted-by":"crossref","first-page":"47","DOI":"10.1001\/jama.291.1.47","article-title":"National use of postmenopausal hormone therapy:annual trends ans response to recent evidence","volume":"291","author":"Hersh","year":"2004","journal-title":"JAMA"},{"issue":"7","key":"10.1016\/j.maturitas.2019.02.009_bib0055","doi-asserted-by":"crossref","first-page":"19","DOI":"10.1186\/1472-6874-7-19","article-title":"Differences in menopausal hormone therapy use among women in Germany between 1998 and 2003","volume":"18","author":"Du","year":"2007","journal-title":"BMC Womens Health"},{"issue":"1","key":"10.1016\/j.maturitas.2019.02.009_bib0060","doi-asserted-by":"crossref","first-page":"53","DOI":"10.3109\/13697137.2014.915516","article-title":"Hot flushes, hormone therapy and alternative treatment:30 years of experience from Sweden","volume":"18","author":"Lindh-\u00c5strand","year":"2015","journal-title":"Climacteric"},{"issue":"6","key":"10.1016\/j.maturitas.2019.02.009_bib0065","doi-asserted-by":"crossref","first-page":"1573","DOI":"10.1001\/jama.292.13.1573","article-title":"Estrogen plus progestin and risk of venous thrombosis","volume":"292","author":"Cushman","year":"2004","journal-title":"JAM"},{"issue":"7","key":"10.1016\/j.maturitas.2019.02.009_bib0070","doi-asserted-by":"crossref","first-page":"840","DOI":"10.1161\/CIRCULATIONAHA.106.642280","article-title":"Hormone therapy and venous thromboembolism among postmenopausal women: impact ot fhe route of estrogen administration and progestogens: the ESTHER study","volume":"115","author":"Canonico","year":"2007","journal-title":"Circulation"},{"issue":"2","key":"10.1016\/j.maturitas.2019.02.009_bib0075","doi-asserted-by":"crossref","first-page":"195","DOI":"10.1016\/j.maturitas.2011.03.011","article-title":"EMAS position statement: managing menopausal women with a personal or family history of VTE","volume":"69","author":"Tremollieres","year":"2011","journal-title":"Maturitas"},{"key":"10.1016\/j.maturitas.2019.02.009_bib0080","article-title":"Hormone therapy for preventing cardiavascular disease in post-menopausal women","volume":"10","author":"Boardman","year":"2015","journal-title":"Cochrane Database Syst. Rev."},{"issue":"24","key":"10.1016\/j.maturitas.2019.02.009_bib0085","doi-asserted-by":"crossref","first-page":"3243","DOI":"10.1001\/jama.289.24.3243","article-title":"Influence of estrogen plus progestin on breast cancer and mammography in healty postmenopausal women: the Women\u2019s Healt Initiative Randomized Trial","volume":"289","author":"Chlebowski","year":"2003","journal-title":"JAMA"},{"issue":"3","key":"10.1016\/j.maturitas.2019.02.009_bib0090","doi-asserted-by":"crossref","first-page":"296","DOI":"10.1001\/jamaoncol.2015.0494","article-title":"Breast cancer after use of estrogen plus progestin and estrogen alone: analyses of data from 2 Women\u2019s Health Initiative Randomized Trials","volume":"1","author":"Chlebowski","year":"2015","journal-title":"JAMA Oncol."},{"issue":"2","key":"10.1016\/j.maturitas.2019.02.009_bib0095","doi-asserted-by":"crossref","first-page":"304","DOI":"10.1016\/0029-7844(94)00383-O","article-title":"Hormone replacement therapy and endometrial cancer risk: a meta-analysis","volume":"85","author":"Gady","year":"1995","journal-title":"Obstet. Gynecol."},{"key":"10.1016\/j.maturitas.2019.02.009_bib0100","article-title":"Continous combined estrogen plus progestin and endometrial cancer: the Women\u2019s Health Initiative Randomized Trial","volume":"108","author":"Chlebowski","year":"2015","journal-title":"J. Natl. Cancer Inst."},{"issue":"7","key":"10.1016\/j.maturitas.2019.02.009_bib0105","doi-asserted-by":"crossref","first-page":"475","DOI":"10.1093\/jnci\/djn058","article-title":"Increased risk of recurrence after hormone replacement therapy in breast cancer survivors","volume":"100","author":"Holmberg","year":"2008","journal-title":"J. Natl. Cancer Inst."},{"issue":"2","key":"10.1016\/j.maturitas.2019.02.009_bib0110","doi-asserted-by":"crossref","first-page":"135","DOI":"10.1016\/S1470-2045(08)70341-3","article-title":"Safety and efficacy of tibolone in breast-cancer patients with vasomotor sumptoms; a double-blind, randomised, non-inferiority trial","volume":"10","author":"Kenemans","year":"2009","journal-title":"Lancet Oncol."},{"issue":"11","key":"10.1016\/j.maturitas.2019.02.009_bib0115","doi-asserted-by":"crossref","first-page":"659","DOI":"10.1007\/s10654-009-9350-y","article-title":"The Swedish personal identity number: possibilities and pitfalls in healtcare and medical research","volume":"24","author":"Ludvigsson","year":"2009","journal-title":"Eur. J. Epidemiol."},{"key":"10.1016\/j.maturitas.2019.02.009_bib0120","doi-asserted-by":"crossref","first-page":"450","DOI":"10.1186\/1471-2458-11-450","article-title":"External review and validation of the Swedish national inpatient register","volume":"11","author":"Ludvigsson","year":"2011","journal-title":"BMC Public Health"},{"issue":"7","key":"10.1016\/j.maturitas.2019.02.009_bib0125","doi-asserted-by":"crossref","first-page":"726","DOI":"10.1002\/pds.1294","article-title":"The new Swedish Prescriebed Drug Register- oppourtunities for pharmacoepidemiological research and experience from the first six months","volume":"16","author":"Wettermark","year":"2007","journal-title":"Pharmacoepidemiol. Drug Saf."},{"issue":"1","key":"10.1016\/j.maturitas.2019.02.009_bib0130","doi-asserted-by":"crossref","first-page":"27","DOI":"10.1080\/02841860802247664","article-title":"The completeness of the Swedish Cancer Register: a sample survey for year 1998","volume":"48","author":"Barlow","year":"2009","journal-title":"Acta Oncol."},{"issue":"3","key":"10.1016\/j.maturitas.2019.02.009_bib0135","doi-asserted-by":"crossref","first-page":"275","DOI":"10.1097\/GME.0000000000000294","article-title":"Use of hormone therapy in Swedish women aged 80 years or older","volume":"22","author":"J\u00e4rvstr\u00e5t","year":"2015","journal-title":"Menopause"},{"issue":"4","key":"10.1016\/j.maturitas.2019.02.009_bib0140","doi-asserted-by":"crossref","first-page":"848","DOI":"10.1093\/humrep\/dev017","article-title":"Hormone rherapy might be underutilized in women with early menopause","volume":"30","author":"Lindh-\u00c5strand","year":"2015","journal-title":"Hum. Reprod."},{"issue":"9","key":"10.1016\/j.maturitas.2019.02.009_bib0145","doi-asserted-by":"crossref","first-page":"1628","DOI":"10.1016\/j.ejca.2014.03.006","article-title":"Effects of hormone replacemnet therapy on the rate of recurrence in endometrial cancer survivors:a meta-analysis","volume":"50","author":"Shim","year":"2014","journal-title":"Eur. J. Cancer"},{"issue":"6","key":"10.1016\/j.maturitas.2019.02.009_bib0150","doi-asserted-by":"crossref","first-page":"593","DOI":"10.1097\/GME.0000000000000611","article-title":"Risk of venous thromboembolism associated with local and systemic use of hormone therapy in peri- and postmenopausal women and in relation to type and route of administration","volume":"23","author":"Bergendahl","year":"2016","journal-title":"Menopause"}],"container-title":["Maturitas"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0378512218308223?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0378512218308223?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,8]],"date-time":"2025-10-08T09:14:14Z","timestamp":1759914854000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0378512218308223"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,5]]},"references-count":30,"alternative-id":["S0378512218308223"],"URL":"https:\/\/doi.org\/10.1016\/j.maturitas.2019.02.009","relation":{},"ISSN":["0378-5122"],"issn-type":[{"type":"print","value":"0378-5122"}],"subject":[],"published":{"date-parts":[[2019,5]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Use of hormone therapy (HT) among Swedish women with contraindications \u2013 A pharmacoepidemiological cohort study","name":"articletitle","label":"Article Title"},{"value":"Maturitas","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.maturitas.2019.02.009","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2019 Elsevier B.V. All rights reserved.","name":"copyright","label":"Copyright"}]}}